Anavex Life Sciences Corp (AVXL)

[boi568]

If you look at that timeline, Anavex would have had to totally remake EXCELLENCE right toward the end of its scheduled run. This is something that may seem possible for a midcap like Biogen (to use a nonrandom example), but would be incredibly disruptive and expensive for Anavex. And there would still be no assurance, given the largely unrecognized social and psychological factors driving the placebo problem, that it would work for RSBQ, which came in at a .063 p value, still alive, if not healthy.

And the remotely measured CGI-I endpoint would still suffer from loss of signal. We would today be years away from the readout; I'm sure everyone would understand. Doc and Investor, for instance -- they'd defend that choice, right?